PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTC:QB GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced today that it had enrolled enough patients to begin closing out the study and starting data analysis. Data analysis will consist of completing the ongoing external review of all biopsy samples, reviewing and entering data from the study case rep
Related Questions
What is the expected timeline for the final data readout and FDA submission?
How will the enrollment numbers compare to the trial’s original targets and expectations?
What are the potential market size and revenue projections for the LuViva Advanced Cervical Scan if FDA approval is granted?
Will there be any upcoming partnership announcements or licensing deals tied to the trial results?
How could the trial outcomes influence the company’s cash burn rate and need for additional financing?
Are there any regulatory or reimbursement hurdles anticipated beyond FDA approval?
How might this trial progress affect the current valuation and price-to-earnings multiples of GTHP?
What are the key risks or uncertainties associated with the external biopsy sample review process?
How does the LuViva platform’s performance metrics compare to existing cervical cancer detection technologies?
What is the anticipated impact on GTHP’s share volume and liquidity once the data is released?